Cancer Resilient Elephants The tumor suppressor Tp53 is the most mutated gene in cancers. Germ-line variations in Tp53 lead to cancer predisposition, as noted in the Li-Fraumeni syndrome (LFS) carriers. Currently, no options are available to delay or prevent cancer development in this population. Conversely, animals such as elephants, are relatively resistant to
The 2025 updated screening recommendations for individuals with Li-Fraumeni syndrome (LFS) are now available from the American Association for Cancer Research (AACR), as published in Clinical Cancer Research on May 15, 2025. These evidence-based updates offer important changes to surveillance protocols aimed at improving early cancer detection and care for individuals living with LFS. The
Li-Fraumeni syndrome (LFS) researchers in Brazil studied factors in determining quality of life issues for women living with LFS who consider risk-reducing mastectomies – one of the few available options to reduce cancer risks in women beyond surveillance. When reviewing this study, keep in mind that the majority of participants in the study carry the
Would you like to participate in a research study at the National Cancer Institute that is developing a mental health resource for young adults with Li-Fraumeni syndrome? Participants will receive a $150 electronic gift card for their participation. Check out this link to see if you are eligible: https://bit.ly/YA-MSC-Study. Scan the QR code or contact
The Li-Fraumeni Syndrome Association (LFSA) is proud to announce that Co-Founder and Board Member Debbie Soprano has been recognized with the 2025 Employee Community Volunteer Award from Boston Children’s Hospital. The award honors Debbie's outstanding commitment to volunteerism through her work with LFSA, where she currently serves as Marketing and Development Chair. Soprano, who
Researchers at the Dana-Farber Cancer Institute concluded that annual whole-body MRIs contribute substantially to detection of asymptomatic localized cancers among individuals with Li-Fraumeni syndrome (LFS). Though interval cancers remain common, Dr. Asaf Maoz, the author of the study, stated that a whole-body MRI serves as a crucial test modality for individuals with LFS that should
Dana-Farber is leading an IRB-approved study that will screen for many of the deadliest cancers with a first-of-its-kind blood test. This test will predict the most likely origin of the cancer signal to help guide the next steps for diagnosis. Note that this will not detect all cancers, and false negatives and false positives
Just published by American Association for Cancer Research (AACR) is the updated version of the “Toronto Protocol,” the widely recognized screening recommendations for Li-Fraumeni syndrome patients, worldwide. Lead by Dr. David Malkin (LFSA Medical & Scientific Board Member and Co-chair of LFSA – Canada), this new perspective provides an up-to-date clinical overview of LFS
The two MHH researchers Lucas John Müntnich and Professor Christian Kratz refer to the cluster analysis of the study, according to which cancer-free survival depends on the classification of the underlying variant. Copyright: Karin Kaiser/MHH. (With permission.) A new form of cluster analysis enables the development of personalized cancer screening tests. As presented
UK researchers conducted a retrospective case-series study of four children diagnosed with solid cancers at age 16 or younger, aiming to assess the time to and survival following a second cancer diagnosis. In those who received radiotherapy for the initial cancer, the median time to a second primary cancer diagnosis was 13.3 years, with a
P.O. Box 6458
Holliston, MA 01746, USA
Phone: 1-833-4MYLFSA (1-833-469-5372)
Email: info@lfsassociation.org
© Copyright 2025 | Li-Fraumeni Syndrome Association | All Rights Reserved | Terms & Conditions | Privacy Policy
